PIK3CB and breast carcinoma: Furthermore, the in vitro and animal model studies revealed that in cancer cells other than breast cancer, where MAPK pathway mutations are rare (COSMIC), KRAS mutations may confer resistance to single agent PI3K pathway inhibitor treatment, as do mutations in BRAF, APC and MYCN.